Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Death domain-containing protein CRADD (CRADD) is an adaptor protein that contains a CARD (caspase recruitment domain) and a death domain, enabling it to interact with and recruit caspase-2 to cell death signaling complexes. Through its interactions, particularly with receptor-interacting protein kinase 1 (RIPK1) and tumor necrosis factor receptor 1 (TNFR1A), CRADD participates in the formation of signaling complexes—such as the PIDDosome—that lead to caspase-2 activation and apoptosis. Mutations in the CRADD gene are linked to certain neurodevelopmental disorders. While CRADD is essential in the apoptotic signaling pathway, it is not currently a direct therapeutic target for any approved drugs, but its key role in cell death makes it relevant in research on cancer and neurodevelopmental diseases[1][2][3][7].
Not applicable; no drugs known to target CRADD directly
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Death domain-containing protein CRADD (CRADD).